Do We Actually Have a Durable Advantage in Healthtech / Digital Health?

Direct answer: In healthtech, a durable advantage is rare — most "moats" are actually capabilities competitors can copy within a funding cycle. To test whether yours is real, run each claimed advantage through VRIO: is it Valuable, Rare, **costly to Imitate, and does your Organization exploit it? Only advantages that pass all four are durable. Regulatory clearances, clinical evidence, payer contracts, proprietary datasets, and workflow embedding tend to survive VRIO in this sector; slick UX, an ML model, and "first-mover" status usually do not.

Why Healthtech Founders Overestimate Their Moat

Digital health is unusually good at generating advantages that feel durable but aren't. A validated EHR integration, a clean interface, a compelling AI triage model — these attract users and investors, but many can be replicated by a well-funded competitor or the incumbent EHR vendor itself.

The pattern is predictable. A company wins on speed and product craft, mistakes early traction for a moat, and scales spending against an advantage that erodes the moment Epic, a payer, or a Series C rival decides to enter. VRIO exists to force an honest conversation before you build a burn plan on top of a copyable capability.

VRIO (Barney's resource-based framework) asks four questions of every resource or capability you claim as an advantage. Answer them plainly, per capability, not for the company as a whole.

Running VRIO on a Healthtech Company

Start by listing your candidate advantages — not aspirations, but things you actually possess today. Typical candidates: FDA clearance (510(k), De Novo, or PMA), clinical validation studies, a proprietary longitudinal dataset, payer or health-system contracts, deep EHR/workflow integration, a specialized clinical team, and network effects across patients or providers.

Then score each on all four dimensions:

Valuable — Does it let you exploit an opportunity or neutralize a threat? In healthtech, "valuable" almost always means it demonstrably improves a payer-relevant outcome (cost, adherence, readmission, quality measure) or removes friction from a clinical workflow. A capability that clinicians admire but that doesn't move a reimbursable metric may not be valuable in the buyer's terms.

Rare — Do few or no competitors control it? An ML model trained on public data is not rare. A dataset covering a specific patient population, condition, and outcome that took years and provider partnerships to assemble often is. Ask: how many organizations could plausibly say the same thing today?

Costly to Imitate — Could a well-resourced competitor replicate it, and at what cost in time, money, and access? This is where most healthtech moats fail or hold. Software is cheap to imitate. What's expensive: regulatory clearances (time + evidence), longitudinal outcomes data (you can't buy years back), causally ambiguous clinical workflows, and switching costs once you're embedded in an EHR and credentialing process. If imitation requires a competitor to also spend three years and run a trial, that's a real barrier.

Organized to capture value — Are your structure, contracts, and go-to-market actually set up to exploit the advantage? A company can hold a rare dataset and still fail here if its sales motion targets the wrong buyer, its contracts don't protect data rights, or its team can't ship into regulated environments. This is the most-overlooked column and often the cheapest to fix.

What "good" looks like: A capability that scores yes on all four — for example, a De Novo clearance plus a proprietary outcomes dataset plus health-system contracts plus an organization built to sell into IDNs — is a sustained competitive advantage. One or two yeses is a temporary edge you should monetize before it closes. Zero to one is a feature, and you should stop marketing it as a moat internally.

Turning the Analysis Into an Execution Plan

VRIO's output isn't a grade — it's a to-do list. Each column suggests a move:

• Valuable but not rare: Race to differentiate or lock in switching costs before parity arrives.
• Rare but imitable: Build the barrier — pursue clearance, deepen data exclusivity, sign exclusive provider partnerships — now, while you're ahead.
• Costly to imitate but not organized: The cheapest, highest-return fix. Realign sales, tighten data-rights clauses, hire regulatory and clinical operators.
• Passes all four: Defend and compound. Concentrate capital here, not on features anyone can copy.

This is where a tool like Percision fits. Full disclosure: I work on content for Percision, so weigh this accordingly. The platform runs your business context through structured reasoning steps across multiple frameworks — VRIO among 27+ — and returns board-ready output in minutes rather than a multi-week engagement: a VRIO breakdown per capability, scenario analysis on what happens if a specific competitor imitates, and financial modeling (DCF, ratios, warning signs) to pressure-test whether the advantage justifies your spend. It's explicitly a co-pilot: you supply the judgment about clinical and regulatory nuance, the AI structures and stress-tests it. That combination of AI structure plus human control mirrors what productivity research from BCG and Harvard Business School found — AI raises quality and speed on well-scoped analytical tasks while human oversight prevents confident errors.

When you don't need it: If you're a solo founder with one product and one obvious advantage, a whiteboard and an afternoon are enough — VRIO is simple by design. If you face a bet-the-company regulatory or M&A question, hire a specialist healthtech advisor or regulatory counsel; that's a human-consultant problem, not a software one. Percision earns its place when you have several capabilities to evaluate, a planning or fundraising cycle demanding board-grade defensibility, and no appetite for an 8–12 week consulting timeline.

Frequently Asked Questions

Is FDA clearance a durable competitive advantage? Often yes on the Imitability dimension — clearance costs time and clinical evidence competitors can't shortcut. But clearance alone isn't a moat if the capability isn't rare or your organization can't sell it. Run it through all four VRIO columns.

Are AI/ML models a moat in healthtech? Rarely by themselves. Models are increasingly imitable; the durable advantage is usually the proprietary, hard-to-assemble data the model trains on and the workflow it's embedded in — not the algorithm.

How often should we re-run VRIO? Each major planning cycle, before a raise, and whenever a well-funded competitor or EHR incumbent signals entry. Advantages erode; the assessment should be a living document.

If you want a structured, board-ready VRIO pass across all your capabilities — with scenario and financial stress-testing built in — you can run your strategy through Percision and keep your leadership team in control of the calls.